Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2027-08-15
Target enrollment:
Participant gender:
Summary
The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant
therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly diagnosed
homologous-recombination proficient(HRP) advanced ovarian cancer (Stage III) after debulking
surgery. Patients will receive AST-201 with rhuGM-CSF(Colony Stimulating Factor) or placebo
with rhuGM-CSF in combination with standard adjuvant chemotherapy(Paclitaxel/Carboplatin).